AUTHORS
Romy Tessa Meier, MSc, Myriam Vaillancourt2, Chi Hau3, Carolien Zeelen4, Suzanne Hofstede-van Egmond Sr, SE5, Leendert Porcelijn, MD6, Masja De Haas Sr, MH7, Eric Boilard, PhD8, Rienk Nieuwland9, Rick Kapur, MD, PhD, MSc10
AFFILIATIONS
1 Amsterdam University Medical Center location University of Amsterdam, Landsteiner Laboratory, Amsterdam, Netherlands, Sanquin Blood Supply Foundation, Amsterdam, Netherlands
2 Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Quebec City, Canada, Université Laval, Quebec City, Canada, Université Laval, Quebec City, Canada
3 Amsterdam University Medical Center, Amsterdam, Netherlands
4 Amsterdam University Medical Center location University of Amsterdam, Landsteiner Laboratory, Amsterdam, Netherlands, Sanquin Blood Supply Foundation, Amsterdam, Netherlands
5 PurSang Diagnostics, Amsterdam, Netherlands
6 PurSang Diagnostics, Amsterdam, Netherlands
7 Leiden University Medical Center, Leiden, Netherlands, Sanquin Blood Supply Foundation, Amsterdam, Netherlands, Sanquin Blood Supply Foundation, Amsterdam, Netherlands
8 Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Quebec City, Canada, Université Laval, Quebec City, Canada, Université Laval, Quebec City, Canada
9 Amsterdam University Medical Center, Amsterdam, Netherlands
10 Amsterdam University Medical Center location University of Amsterdam, Landsteiner Laboratory, Amsterdam, Netherlands, Sanquin Blood Supply Foundation, Amsterdam, Netherlands
ABSTRACT
Introduction:
Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder characterized by the occurrence of thrombocytopenia and thrombosis, driven by antibodies directed against platelet factor 4/heparin complexes (anti-PF4/H) which cause FcγRIIa-mediated platelet activation. While the role of platelets is well-recognized in the pathophysiology of HIT, the contribution of platelet-derived extracellular vesicles (pEVs) to date remains remarkably understudied, despite first being suggested to be relevant in HIT in 1994 (Warkentin et al, Blood 1994), and regardless of the rapidly evolving, improved methodologies for EV detection in the last few years.
Aim of the study:
To use the current state-of-the art methodology for EV detection in order to A) investigate the concentration of circulating plasma pEVs in HIT patients in relation to anti-PF4/H and FcγRIIa-dependent platelet aggregation, B) study the ability of an anti-PF4/H HIT monoclonal antibody to activate platelets and induce FcγRIIa-mediated pEV production with characterization of pEV activation status.
Methods:
A) healthy individuals (n=12) and suspected HIT patients (n=10) were obtained from PurSang Diagnostics, Amsterdam, The Netherlands (national reference center for HIT diagnostics). Suspected HIT patient samples were tested in the anti-PF4/H ELISA, as well as for their ability to induce FcγRIIa-dependent platelet aggregation in the Heparin-Induced Platelet Activation Assay (HIPAA). We assessed the concentration of CD41+ pEVs using flow cytometry according to the MIFlowCyt-EV guidelines (Welsh et al, J Extracell Vesicles 2020). B) Donor platelets were treated with HIT monoclonal anti-PF4/H 5B9, PF4 and heparin, with and without blockade of FcγRIIa using antibody IV.3, with assessment of platelet activation using flow cytometry (CD62P, phosphatidylserine; PS) and pEV release (concentration) and pEV activation (CD62P, PS).
Results:
A) We found that of the 10 suspected HIT patients, 6 patients tested negative in the anti-PF4/H ELISA, as well as in the HIPAA. 4 patients tested positive in both the anti-PF4/H ELISA and in the HIPAA, and demonstrated abrogated platelet aggregation with blockade of Fcγ These 4 patients demonstrated significantly more circulating CD41a+ pEVs (mean 8.0 x 107 EVs/mL) compared to healthy donors (mean 2.5 x 107 EVs/mL). CD41a+ EV concentrations in plasma samples from the 6 patients who tested negative in the anti-PF4/heparin ELISA as well as in the HIPAA did not differ significantly from healthy controls (mean 5.8 x 107 EVs/mL). Detected EVs were between 100 and 1000 nm and had a refractive index < 1.42 distinguishing them from lipoproteins and larger particles present in the plasma.
B) 5B9+PF4+heparin were found to activate platelets (increased expression of CD62P and PS) in a FcγRIIa-dependent manner. In line with this, we also observed increased CD41a+pEVs for 5B9+PF4+heparin (mean 5.5 x 105 EVs/mL), compared to 5B9 alone (mean 4.1 x 103), PF4 alone (mean 2.0 x 103) and heparin alone (mean 6.1 x 103). We found that in particular more PS+/CD41a+ pEVs (mean 5 x 105 EVs/mL) were released compared to CD62P+/CD41a+ EVs (mean 0.9 x 105 EVs/mL). Blocking of platelets with FcγRIIa-blocking antibody IV.3, resulted in a significant reduction of both PS+/CD41a+ (mean 1.3 x 103 EVs/mL) and CD62P/CD41a+ (mean 1.9 x 103 EVs/mL) EVs.
Conclusion and discussion:
Using state-of-the-art methodology for EV detection, we demonstrate as a proof-of-concept that CD41a+ pEVs are elevated in plasma of HIT patients who tested positive for both anti-PF4/H as well as for FcγRIIa-dependent platelet aggregation, compared to healthy controls. In addition, using HIT-like monoclonal antibody 5B9+PF4+heparin we observed increased platelet activation as well as increased CD41a+ pEV release, both in an FcγRIIa-dependent manner. We predominantly observed the release of PS+/CD41a+ pEVs, considering PS expression has been suggested to be a feature of procoagulant platelet phenotype capable of promoting thrombin generation, this may play a role in the procoagulant immune response in HIT. Further studies in larger patient cohorts are warranted to establish the contribution of pEVs to HIT pathophysiology, in particular HIT-associated thrombosis, and their potential value as a diagnostic biomarker.
DISCLOSURES
Romy Tessa Meier, MSc: No relevant conflicts of interest to declare.